STEAP4 Target NQO1 Mediates Colon Tumorigenesis J Cell Sci. 2025 Apr 10 ... (NQO1) signaling pathway, inducing apoptosis and autophagy, leading to substantial reductions in xenograft tumor growth. In contrast, STEAP4 overexpression amplifies ROS production and activates the NRF2-NQO1 pathway in a ferric iron-dependent manner. Notably ...

We review here the natural and new quinones activated by NQO1, the catalytic inhibitors, and the ensuing cell death mechanisms. Further, the cancer-selective expression of NQO1 has opened excellent opportunities for distinguishing cancer cells/tissues from their normal counterparts.

In a comprehensive study, these authors demonstrated that overexpression of NQO1 in RKO colon tumor xenografts led to significantly increased tumor growth rate and that knockdown of NQO1 inhibited growth but only in the context of functional HIF-1α.

It has been known that NQO1 is expressed at high levels in numerous human cancers, including breast, colon, cervix, lung, and pancreas, as compared with normal tissues. This implies that tumors can be preferentially damaged relative to normal tissue by cytotoxic quinone drugs.

Aug 8, 2014 · In the current study, we aimed to conduct a comprehensive meta-analysis of the association between only invasive colorectal neoplasm and the risk of NQO1 C609T polymorphism in both Caucasians and Asians. We also explored the interaction between NQO1 genotype and smoking status.

Feb 12, 2025 · Quinone oxidoreductase (NQO1), a cytosolic flavoprotein, is important for reprogramming cancer cell metabolism. Therefore, NQO1’s function in aerobic glycolysis and impact on colorectal cancer (CRC) development and progression was investigated.

This review outlines the NQO1 structure, mechanism of action to inhibit the cancer cell, functions of NQO1 against oxidative stress, drugs acting on NQO1 pathways, clinical significance.

6 days ago · Notably, bioactivatable drugs targeting NQO1 are highly effective in eradicating STEAP4-overexpressing colon cancer cells. These findings highlight the potential of targeted therapeutic interventions for CRC, particularly through STEAP4 modulation.

Oct 1, 2000 · NAD(P)H:quinone oxidoreductase (NQO1) is a polymorphic enzyme involved in the detoxification of potentially mutagenic and carcinogenic quinones. The homozygous C609T NQO1 genotype resulting in loss of reductase activity is found in 2–20% of individuals.

We describe the establishment of an isogenic human tumor cell model for DT-diaphorase expression. An expression vector was used in which the human elongation factor 1 α promoter produces a bicistronic message containing the genes for human NQO1 and puromycin resistance.